Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cabergoline Effect on Blood Sugar in Type 2 Diabetics

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2011 by Mashhad University of Medical Sciences.
Recruitment status was  Not yet recruiting
Information provided by (Responsible Party):
Haleh Rokni Yazdi, Mashhad University of Medical Sciences Identifier:
First received: October 24, 2011
Last updated: NA
Last verified: October 2011
History: No changes posted
Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.

Condition Intervention
Diabetes Type 2
Drug: Cabergoline

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics

Resource links provided by NLM:

Further study details as provided by Mashhad University of Medical Sciences:

Primary Outcome Measures:
  • FBS (fasting blood sugar) [ Time Frame: 30days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • HbA1C [ Time Frame: 30days ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: January 2012
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Cabergoline
    0,5mg per week
    Other Name: Dastinex

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes
  • HbA1C>7

Exclusion Criteria:

  • HbA1C>10
  • Psychiatric disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Haleh Rokni Yazdi, assisstant professor, Mashhad University of Medical Sciences Identifier: NCT01459601     History of Changes
Other Study ID Numbers: CabergolinDM 
Study First Received: October 24, 2011
Last Updated: October 24, 2011
Health Authority: Iran: Ethics Committee

Keywords provided by Mashhad University of Medical Sciences:
diabetes mellitus

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Antineoplastic Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on October 28, 2016